Eli Lilly Launches Second Education Program for Medical Students
Eli Lilly and Company has launch of another medical student education program, an internship for aspiring physicians. The Lilly Medical Student Intern Program, the second phase of its medical student programs, offers opportunities for medical students between their first and second years to work alongside healthcare professionals in the pharmaceutical industry to gain scientific knowledge and experience in several areas, including preclinical research, clinical trial development, medical affairs, regulatory affairs, bio-ethics and patient safety.
Six students from Marian University College of Osteopathic Medicine will be the first to participate in the intern program at Eli Lilly and Company's Indianapolis headquarters. Students will expand their knowledge of the industry by spending time at other facilities, including Covance and Elanco, networking with executive leadership and participating in team-building activities with other summer interns across the company.
"We see a great synergy in the making, as these students will have the opportunity to obtain unique, real-world experiences in the realm of drug discovery and development and the myriad of regulatory, legal and business aspects of the pharmaceutical industry," said Dr Bryan Larsen, PhD, associate dean for biomedical sciences, Marian University College of Osteopathic Medicine. "And Marian University will enjoy an unprecedented opportunity to showcase some of its very promising student doctors to the leaders of one of the most revered pharmaceutical companies in the world," he added.
This is the second medical student program launched by Lilly this year. In February, Lilly announced a new partnership with Tulane University School of Medicine to debut the Medical Student Rotation Program, a 4-week experiential learning program for fourth-year medical students.
The 10-week internship program with Marian University students, which will run from May through August, matches interns with projects based on their skills and interests. Experienced, knowledgeable mentors will help students gain hands-on experience and explore diverse career options in healthcare.
"By participating in this program, students will gain experience in drug development, interact with professionals in a variety of medical roles, and further develop leadership skills," said Katie Sugarman, MD, Senior Director, Global Regulatory Affairs — Oncology, Eli Lilly and Company, and a Lilly mentor in the new medical student programs. "We believe this internship will provide students with a better understanding of how physicians contribute to patient outcomes in this area of healthcare."
Both the Intern Program and Medical Student Rotation Program highlight Lilly's ongoing commitment to medical education.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance